POPE-2: Colchicine to prevent pericardial effusion after cardiac surgery

The incidence of asymptomatic pericardial effusion after cardiac surgery is high. The aim of this study was to evaluate whether colchicine would be able to reduce the volume of postoperative pericardial effusion. This multicenter, double-blind, placebo-controlled study, randomized 197 patients with high risk of cardiac tamponade determined by the presence of persistent pericardial effusion from moderate to severe for more than 7 days after surgery using 1 mg colchicine versus placebo. At 14 days after randomization, no difference was observed in the volume of effusion or tamponade incidence between the two branches. 

4_philippe_meurin
Philippe Meurin
2014-08-31

Original title: Colchicine for Post- operative Pericardial Effusion: The post-operative pericardial effusion (POPE-2) Study. A multicenter, double-blind, randomized trial.

More articles by this author

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks...

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may...

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued...

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated dose of randomized statin alirocumab 75 mg...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...